- Description
- Additional Information
- Readable Documents
- Assay Principle
- Reviews
Key Benefits
- Homogenous assay for active caspase 3/7.
- Breakthrough in cell lysis buffer and preservation of caspase activity.
- Results in a no-wash, one-step assay.
- No need to wash out media from cell samples, just add the reagent directly to your experimental samples.
- Easy to Use: No need to make cell lysates or run Western blots.
- Works with suspension and adherent cells.
Additional information
| Kit Size | 100, 500, 1000 |
|---|
Cell Technology’s APO 3/7 HTS Assay utilizes the quenched (z-DEVD)2-R110 peptide substrate for caspase 3/7 detection. The absorption and emission properties of the R110 dye are suppressed when attached to the z-DEVD peptide sequence. When R110 is cleaved away, by active caspase3/7, form the quenching DEVD sequence, the free dye excites at 488nm and emits at 515-530 nm. As a result of a novel and proprietary Lysis Buffer System, the APO 3/7 HTS Assay is a homogenous platform that can be utilized for high throughput fluorescence plate reader applications. The reagent is directly added to the samples thus eliminating any wash steps.
Figure. In this figure, Jurkat cells were stimulated with various concentrations of staurosporine for 3 hours, after which caspase 3/7 activity was analyzed using the APO 3/7 HTS kit.
| Document Title |
| Apo3HTSprotocol |
| APO 3 HTS Datasheet |
| msds.APO3HTS |
| Reference |
| Slee, E. A., C. Adrain, and S. J. Martin. 1999. Serial Killers: ordering caspase activation events in apoptosis. Cell Death and Differ. 6:1067-1074. |
| Walker, N. P., R. V. Talanian, K. D. Brady, L. C. Dang, N. J. Bump, C. R. Ferenz, S. Franklin, T. Ghayur, M. C. Hackett and L. D.Hammill. 1994. Crystal Structure of the Cysteine Protease Interleukin-1ß-Converting Enzyme: A (p20/p10)2 Homodimer. Cell 78:343-352. |
| Wilson, K. P., J. F. Black, J. A. Thomson, E. E. Kim, J. P. Griffith, M. A.Navia, M. A. Murcko, S. P. Chambers, R. A. Aldape, S. A. Raybuck, and D. J.Livingston. 1994. Structure and mechanism of interleukin-1 beta converting enzyme. Nature 370: 270-275. |
| Rotonda, J., D. W. Nicholson, K. M. Fazil, M. Gallant, Y. Gareau, M. Labelle,E. P. Peterson, D. M. Rasper, R. Ruel, J. P. Vaillancourt, N.A. Thornberry and J.W. Becker. 1996. The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis. Nature Struct. Biol. 3(7): 619-625. |
| Kumar, S. 1999. Mechanisms mediating caspase activation in cell death. Cell Death and Differ. 6: 1060-1066. |
| Alnemri, E.S. et al (1996) Cell 87:171 |
| Trends Biochem Sci 22,388 (1997) |
| Part# | Reagent | Temperature |
| Part# 4004 | Caspase 3/7 Reagent (z-DEVD) 2 Rodamine 110, 1 Vial | -20C |
| Part# 3005 | Cell Lysis Buffer, 1 Bottle | 2-8C |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
还有如果用气相做糖的鉴别的话,需要样品量大不大?怎么衍生化?
不好意思,我是学药分的,对植化比较外行,请详细些,谢了先!
1.用这个人类膜蛋白c端末短肽(14个残基,478-492)偶联KLH生产的兔多克隆抗体(abcam公司产品)
2.用大鼠的同源膜蛋白c端(具体哪一段不清楚)生产的兔多克隆抗体(abcam公司产品),我比对过人和大鼠的这个膜蛋白,同源性很高,c端完全一样(这里也很困惑公司为什么说是大鼠来源的)
3.用这个人类膜蛋白两个跨膜区之间的一个loop环序列(42个残基,218-260)生产的兔多克隆抗体(santa公司产品)
这三个抗体理论上来讲哪个更好些呢?请有经验的大虾给予指点!
另:我听说abcam的抗体比santa好,是吗?
在线等,急!
大多数药物在体内都是和特异性受体相互作用,改变细胞的生理生化功能而产生效应。目前已经确定的受体有30多种,根据受体存在的标准,受体可大致分为三类:
1.细胞膜受体:位于靶细胞膜上,如胆碱受体、肾上腺素受体、多巴胺受体、阿片受体等。
2.胞浆受体:位于靶细胞的胞浆内,如肾上腺皮质激素受体、性激素受体。
3.胞核受体:位于靶细胞的细胞核内,如甲状腺素受体。
另外也可根据受体的蛋白结构、信息转导过程、效应性质、受体位置等特点将受体分为四类:
1.含离子通道的受体(离子带受体):如N-型乙酰胆碱受体含钠离子通道。
2.G蛋白偶联受体:M-乙酰胆碱受体、肾上腺素受体等。
3.具有酪氨酸激酶活性的受体:如胰岛素受体。
4.调节基因表达的受体(核受体):如甾体激素受体、甲状腺激素受体等。
有些受体具有亚型,各种受体都有特定的分布部位核特定的功能,有些细胞也有多种受体。
在一些解热镇痛药注射剂中,为避免药物发黄变色,又加入了氨基酸抗氧化剂(除了亚硫酸氢钠外)。氨基酸抗氧化剂有哪些呢,常用的。查了一下,含S的抗氧化剂有甲硫氨酸(Met)和半胱氨酸(Cys),是这些吗?还是有其他常用的呢?
类医疗器械?谢谢!
以前听说过设计引物,以引物互为模板进行PCR获得的引物二聚体就是目的片段
有没有人具体操作过呢?应该注意什么问题呢?比如引物设计,体系,PCR程序
就是蛋白质分子的小片断
是氨基酸形成的

